Experimental study of the antitumor effect of aurumacryl

Gold polyacrylate (aurumacryl) belonging to a new class of compounds for oncology — metal polyacrylates — was shown to exhibit strong antitumor activity. Aurumacryl causes 80—90% growth inhibition in vivo of murine solid tumors (Lewis lung carcinoma, Ca-755 adenocarcinoma, and Acatol adenocarcinoma)...

Full description

Saved in:
Bibliographic Details
Published in:Russian chemical bulletin 2017-12, Vol.66 (12), p.2333-2338
Main Authors: Ostrovskaya, L. A., Korman, D. B., Grehova, A. K., Osipov, A. N., Bluhterova, N. V., Fomina, M. M., Rikova, V. A., Abzaeva, K. A.
Format: Article
Language:English
Subjects:
60 APPLIED LIFE SCIENCES
Acrylic resins
Anticancer properties
APOPTOSIS
BUILDUP
CARCINOMAS
Cell death
Chemistry
Chemistry and Materials Science
Chemistry/Food Science
CHEMOTHERAPY
CONTROL
Full Article
GOLD
IN VITRO
IN VIVO
Inorganic Chemistry
INORGANIC, ORGANIC, PHYSICAL AND ANALYTICAL CHEMISTRY
LUNGS
MAMMARY GLANDS
Organic Chemistry
POLYACRYLATES
TUMOR CELLS
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gold polyacrylate (aurumacryl) belonging to a new class of compounds for oncology — metal polyacrylates — was shown to exhibit strong antitumor activity. Aurumacryl causes 80—90% growth inhibition in vivo of murine solid tumors (Lewis lung carcinoma, Ca-755 adenocarcinoma, and Acatol adenocarcinoma) compared to the control and induces cell death in vitro in 60% of MCF-7 human breast carcinoma cells. Substantial changes in proliferation kinetics of the surviving fraction of tumor cells following treatment with aurumacryl were observed, which are related to the predominant accumulation (93%) of cells in the proliferative resting phase G 0 and a substantial decrease in the percentage of proliferating cells (7%). These data provide evidence that the cells that survive lose reproductive ability under treatment with aurumacryl.
ISSN:1066-5285
1573-9171
DOI:10.1007/s11172-017-2025-z